Breaking News, Collaborations & Alliances

TriLink Extends EyeGene Partnership for COVID-19 Vaccine Development

CleanCap technology to be used in the production of EG-COVID mRNA COVID-19 vaccine for clinical trials.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TriLink BioTechnologies, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, said that it expects to supply its proprietary CleanCap mRNA capping technology and the modified nucleoside, uridine triphosphate, to EyeGene for production of EyeGene’s mRNA COVID-19 vaccine, EG-COVID, which recently received approval to begin clinical trials from the South Korean Ministry of Food and Drug Safety (MFDS). This collaborat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters